Cargando…
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more than 90% in certain cancer types such as pancreatic adenocarcinoma. Although historically considered to be undruggable, a...
Autores principales: | Merz, Valeria, Gaule, Marina, Zecchetto, Camilla, Cavaliere, Alessandro, Casalino, Simona, Pesoni, Camilla, Contarelli, Serena, Sabbadini, Fabio, Bertolini, Monica, Mangiameli, Domenico, Milella, Michele, Fedele, Vita, Melisi, Davide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991835/ https://www.ncbi.nlm.nih.gov/pubmed/33777798 http://dx.doi.org/10.3389/fonc.2021.638360 |
Ejemplares similares
-
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
por: Gaule, Marina, et al.
Publicado: (2022) -
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
por: Merz, Valeria, et al.
Publicado: (2022) -
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab
por: Zecchetto, Camilla, et al.
Publicado: (2023) -
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer
por: Cavaliere, Alessandro, et al.
Publicado: (2019) -
The Multifaceted Role of TGF-β in Gastrointestinal Tumors
por: Sabbadini, Fabio, et al.
Publicado: (2021)